Legend Biotech ROA 2019-2022 | LEGN

Current and historical return on assets (ROA) values for Legend Biotech (LEGN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Legend Biotech ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-03-31 $-0.35B $1.04B -36.07%
2021-12-31 $-0.39B $1.12B -45.24%
2021-09-30 $-0.36B $0.81B -47.07%
2021-06-30 $-0.30B $0.88B -40.82%
2021-03-31 $-0.34B $0.62B -48.40%
2020-12-31 $-0.30B $0.72B -47.35%
2020-09-30 $-0.31B $0.71B -58.08%
2020-06-30 $-0.27B $0.77B -76.02%
2020-03-31 $-0.17B $0.37B -101.07%
2019-12-31 $-0.13B $0.29B -184.72%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.835B $0.090B
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00